Want to join the conversation?
$PFE said the Phase 3 INO-VATE ALL study results showed improvement over chemotherapy on various measures including complete hematologic remission and progression-free survival. This is an open-label, randomized study evaluating safety and efficacy of inotuzumab ozogamicin in adults with relapsed CD22-positive acute lymphoblastic leukemia.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.